3D Systems has named Jeffrey Creech as executive vice president and chief financial officer and announced the creation of a new position, president of regenerative medicine, to be filled by Harriss Currie. Andy Johnson, who served as interim chief financial officer, will continue in his roles as chief corporate development officer and chief legal officer.
Reporting to 3D Systems President and CEO Dr. Jeffrey Graves, Creech will lead all aspects of the company’s global financial organization, while Currie will lead all elements of 3D Systems’ regenerative medicine operations. Creech brings over 25 years of finance and business transformation experience to 3D Systems, most recently serving as a senior director of executive consulting firm Finley Group and previously as COO and CFO of Nutramax Laboratories. He also held leadership roles at Springs Creative Products Group, serving as president and chief operating officer, and at Jefferson Wells, where he was national director of COE business transformation.
Currie has 30 years of leadership experience, with a focus on building emerging businesses. He spent over 20 years at Luminex Corporation, a DiaSorin company known for bioassay technology for life science applications. As senior vice president and chief financial officer at Luminex, Harriss helped lead the company’s growth from a startup to a valuation of more than $500 million. His career also includes senior management positions at Impulse Dynamics and SpectraCell Laboratories. In his new position at 3D Systems, Currie will oversee 3D Systems’ human organs partnership with United Therapeutics, as well as the recently formed Systemic Bio Business, which was established to focus on bioprinting solutions for the pharmaceutical industry.
Source: www.3dsystems.com